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Ahmed glaucoma valves in refractory glaucoma:
a 7-year audit
Peter K Wishart, Anshoo Choudhary, David Wong
ABSTRACT
Purpose To present the long-term results of Ahmed
glaucoma valve (AGV) implantation.
Methods Consecutive case series of 94 eyes with AGV
implantation over 7 years. Temporary tube ligation with
C3F8 gas fill was used in high-risk eyes (group G&L) and
compared with standard implantation in both phakic
(group A) and pseudophakic/aphakic eyes (group B).
Success was intraocular pressure (IOP) of 6 mm Hg or
greater and 21 mm Hg or less and/or IOP reduction of
20% or greater.
Results Average follow-up was 28.9620.3 months. The
mean preoperative IOP changed from 30.868.2 to
19.767.6 mm Hg and mean preoperative medications
changed from 3.361.2 to 1.261.1 at the final visit.
Cumulative probability of survival at 1 and 4 years was
89.1% and 72.9%. There was no statistically significant
difference in success between the three groups, but
complications due to postoperative hypotony (six eyes)
only occurred in group B. Other complications were
corneal decompensation (three eyes), tube erosion (six
eyes) and aqueous misdirection (four eyes).
Conclusions AGV implantation offered good long-term
IOP control with a success rate of 78.7%. The authors
recommend C3F8 gas fill and temporary tube ligation in
eyes at high risk of postoperative hypotony and the use
of donor sclera or human pericardial patch to prevent
tube erosion.
Glaucoma tube implants (aqueous shunts) are used
for the surgical treatment of uncontrolled intraocular
pressure (IOP) in eyes with refractory glaucoma, and
reported success rates are between 60 and 82%
at 2 years,1e5 with a reported 10% per year failure
rate.6 The most serious immediate complications of
aqueous shunts are those related to postoperative
hypotony, including shallow and flat anterior cham-
bers, choroidal detachments and suprachoroidal
haemorrhage (SCH).7e9 Erosion of the tube through
the conjunctiva is a potential hazard of aqueous
shunts and may lead to endophthalmitis.10 Corneal
endothelial failure (CEF) has been described as the
principal long-term complication.6
Toavoidpostoperativehypotonynon-valved shunts
are now implanted with a temporary ligature of the
tube. The Ahmed glaucoma valve (AGV; Rancho
Cucamonga, California, USA) has a silicone elastomer
membrane held in a polypropylene or silicone body
forming a non-obstructive valve that should prevent
excessive aqueous drainage and anterior chamber
collapse. However, postoperative hypotony has been
reported in up to 29% of cases1 4 5 11e13 of AGV
implantation, causing flat anterior chambers in up to
10% of eyes and SCH in up to 5% of eyes.1 2 11 13e15
We report an audit of consecutive cases of AGV
implanted from 2002 to 2008 by one surgical team,
highlighting our attempts to reduce the incidence of
serious complications such as postoperative hypotony
and tube erosion. Sudden hypotony following surgical
decompression is reported tobe theprecipitating factor
responsible for the occurrence of SCH with aphakia,
pseudophakiaandpreviousvitrectomy identifiedas the
major risk factors for SCH.16e18 FromSeptember 2004,
we attempted to avoid hypotony in eyes with these
risk factors by using anterior chamber C3F8 gas fill
coupled with polyglactin (Vicryl, Ethicon) suture liga-
tion as described by Franks and Hitchings19 for use in
non-valved implants. To prevent conjuctival tube
erosionweused a scleral patch graft,20 a scleral rotation
flap21 or a pericardial patch graft.22 As this gas and
ligature (G&L) technique might carry the risk of
inducing a postoperative IOP spike or prolonging the
‘hypertensive phase’ commonly seen with AGV
implantation,2 11 14 we compared the postoperative
pressure profiles of our G&L eyes with those of glau-
comatous eyes undergoing standard AGV implanta-
tion in our unit during the same time period.
PATIENTS AND METHODS
Patient selection
The indication for AGV implantation was the pres-
ence of glaucoma with medically uncontrolled IOP
and the presence of factors thatwouldmake filtering
surgery unlikely to be successful, such as uveitis,
previous failed filtering surgery or aphakia. All eyes
undergoing AGV implantation from January 2002 to
July 2008 were included in this consecutive case
series. The majority of the implants were the S-2
single plate model. From January 2008 onwards we
implanted only the FP-7 model (single plate silicone
body). Surgery was performed by one of the authors
(PKW) in all but six eyes, inwhich surgerywas under
the supervision of PKW.
Data collection
For each patientwe documented the age, gender, race,
glaucomadiagnosis, total number of operationsbefore
the AGV insertion, presenting IOP, preoperative IOP
and visual acuity, gonioscopy and corneal thickness
measured by ultrasonic pachymetry (‘Pachmate’;
DGH Technologies, Exton, Pennsylvania, USA). Full
ophthalmic examination with visual acuity, Gold-
mann applanation tonometry and fundus examina-
tionwere performed at all visits. Themean number of
medications was calculated by the addition of each
medication as one unit, with fixed combinations
scored as two and systemic acetazolamidedDiamox
SR (Goldshield Pharmaceuticals, Croydon, UK), dose
250 mg twice a daydalso scored as two units. Post-
operatively the IOP and visual acuity were noted at
St Paul’s Eye Unit, Royal
Liverpool and Broadgreen
University Hospital, Liverpool,
UK
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day 1, day 7, month 1, month 2 and thereafter at 3e6-monthly
intervals.
Technique
Following a case of SCH after AGV implantation in an aphakic
eye in September 2004, we modified our technique of AGV
implantation such that all high-risk eyes undergoing AGV
implantation had 14% perfluoropropane (C3F8) gas injection
into the anterior chamber by means of a paracentesis and liga-
tion of the tube with a 5 ‘O’ Vicryl suture. Such cases are
reported as our G&L group. Eyes having standard implantation
without gas or ligature are reported as standard group A (phakic
eyes) and standard group B (aphakic/pseudophakic eyes). On
implanting an AGV it is necessary first to prime the valve with
balance salt solution (Alcon, Fort Worth, Texas, USA), which
creates a small drainage hole at the posterior edge of the elas-
tomer membrane. To prevent injected C3F8 gas escaping up the
tube and through this hole, temporary occlusion of the tube was
provided by a 5 ‘O’ Vicryl ligature. The ligature was tied with
three throws of the suture to achieve a compression rather than
occlusion of the tube and pulled tight enough to prevent the
escape of gas from the anterior chambers up the tube. The high
surface tension of a C3 F8 gas bubble should prevent anterior
chamber collapse in the event of excess aqueous leak round the
tube or the sudden development of choroidal detachments. Tube
implantation in all cases was by means of a ‘23’-gauge needle
track 2 mm posterior to the limbus through full thickness scleral
tissue into the anterior chamber to achieve a water-tight fit. To
cover the tube, we used either an autologous scleral rotation flap
(figure 1),21 or a donor scleral or pericardial patch.20 We initially
used bovine pericardium: Tutopatch (Tutogen GMBh,
Neunkirchen am Brand, Germany), but after observing overlying
conjunctival melt in some cases we changed to human donor
pericardium: Tutoplast (Tutogen GMBh). The conjunctiva was
closed with interrupted 8 ‘O’ or 10 ‘O’ Vicryl sutures. No anti-
metabolites were used in this study. Postoperative topical
steroids, Pred Forte (Allergan, Irvine, California, USA) were
given four times a day for 1e2 months and atropine drops twice
a day for 2 weeks.
Outcome measures
Success was defined as in the Tube Versus Trabeculectomy
Study7 23: IOP 6 mm Hg or greater and 21 mm Hg or less with
or without medication and/or IOP reduction of 20% or greater
relative to preoperative values. Failure was defined as IOP greater
than 21 mm Hg or not reduced by 20% below baseline on two
consecutive follow-up visits after 3 months, IOP of 5 mm Hg or
less on two consecutive follow-up visits after 3 months, re-
operation for glaucoma, or loss of light perception vision. Eyes
that had not failed and were not on supplemental medical
therapy were considered complete successes. Eyes that had not
failed but required supplemental medical therapy were defined
as qualified successes.
Statistical analysis
Statistical analysis was performed using the SPSS 16 software for
Windows. Descriptive statistics were employed to summarise
demographics andoutcome characteristics of the groups. Student’s t
test was used to determine the significance of any differences in the
continuous variables within each group. The Wilcoxon signed rank
test was used to compare the pre and postoperative antiglaucoma
medication scores. The one-way analysis of variance was used to
comparemeans of the three groups and post hoc tests were used for
comparisons between groups. A p value of less than 0.05 was taken
as statistically significant.Thecumulativeprobabilityof successwas
derived using the KaplaneMeier survival curve and the log-rank test
was used to compare survival between groups. The time to failure
was defined as the time from AGV implantation to re-operation for
glaucoma or the first of the two consecutive visits after 3 months
when the patient had hypotony or uncontrolled IOP.
RESULTS
Ninety-four eyes of 83 patients underwent AGV implantation
with amean follow-up of 28.9620.3 months (range 2e84). These
included 51 high-risk eyes that underwent AGV with gas fill and
ligature (G&L group; 50 aphakic/pseudophakic and one myopic
phakic) and 43 eyes that underwent standard AGV implantation,
comprising 28 phakic (standard group A) and 15 pseudophakic/
aphakic (standard group B) eyes. Patient demographics and
preoperative characteristics are detailed in table 1.
The G&L group and standard group B had a significantly higher
meanage (66.5 and65.6 years vs50.5 years) andnumberofprevious
operations (2.4 and 2.1 vs 0.9) comparedwith the standard groupA
(p¼0.001 and 0.000, table 2, figure 2). There was no significant
difference between the groups in respect of the presenting IOP,
preoperative IOP and number of medications (p>0.05).
The mean preoperative and postoperative IOP, antiglaucoma
medication, outcome and complications are detailed in table 2.
Postoperative IOP control with time is shown in figure 2. The
change in IOP was statistically significant at all times post-
operatively in all groups. The mean IOP at day 1 and day 7 was
significantly higher in theG&L group comparedwith the standard
A and B groups (p¼0.000 and 0.006). There was no significant
difference in IOPat days 1 and 7 between standard groups A andB.
On the first postoperative day, eight eyes in the G&L group had
IOP greater than 30 mm Hg (mean 38 mm Hg, range 32e45 mm
Hg), which was relieved by tapping the gas bubble by needle
pressure on the site of the paracentesis. There was no significant
difference in thefinal IOP between the groups (p¼0.56). Themean
number of medications reduced significantly in all groups (table 2,
p<0.001) and there was no significant difference in the post-
operative medication scores of the three groups (p¼0.4). At finalFigure 1 Silicone tube of Ahmed glaucoma valve is covered by
a scleral rotation flap.
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follow-up success was achieved in 75% eyes in the G&L group,
82.1% in standard group A and 73.4% in standard group B.
Complete success was achieved in 30.8% eyes in the G&L group,
39.2% in standard group A and 13.3% in standard group B.
KaplaneMeier survival analysis is detailed in figure 3. The
cumulative probability of maintaining an IOP of 6 mmHg or
greater and 21 mmHg or less and/or a 20% or greater drop in IOP
for the G&L group, standard group A and standard group B was
87.9%, 92.4% and 86.7% at 1 year and 62.9%, 71.5% and 86.7% at
4 years, with a mean survival time of 38.7 months, 66.6 months
and 62.7 months. There was no statistically significant difference
in the survival between groups (p¼0.19).
Complications are summarised in table 2. CEF directly attrib-
utable toAGVimplantation occurred in only one eye.This eyewas
in the G&L group and followed the development of aqueous
misdirectionwith aflat anterior chamber after AGVimplantation.
CEF worsened after AGV implantation in two eyes with previous
intraocular surgery. Late CEF was seen in three other eyes with
pre-existing corneal damagedtwo traumatic aphakic eyes, one
iridocorneal endothelial syndrome eye. Therewas one case of SCH
occurring in a 73-year-old aphakic eye with previous vitrectomy
that underwent standard AGV implantation. Visual acuity was
reduced to perception of light but after drainage of the haemor-
rhage and vitrectomy with injection of heavy oil, the vision
recovered to 6/9. Aqueous misdirection occurred in four pseudo-
phakic eyes after AGV implantation. Zonulo-hyaloido-vitrec-
tomy24 was effective in correcting the aqueous misdirection in all
cases. Three of the four cases occurred in eyes with previous acute
angle closure glaucoma. Three eyes with advanced visual field loss
had a reduction of vision to levels of hand movements by final
follow-up.
DISCUSSION
The purpose of this report is to share our experience of the success
and hazards attendant on AGV implantation and to describe our
attempts to improve the safety of AGV implantation. Sudden
postoperative hypotony following tube implantation can lead to
serious complications: shallow/flat anterior chambers, the devel-
opment of choroidal effusions or SCH. SCH is associated with
sudden lowering of IOP with aphakic, pseudophakic and vitrec-
tomised glaucomatous eyes especially at risk of this complication
following tube implant surgery,16e18 and SCH can follow even
relatively minor surgical procedures in glaucomatous eyes.25 26
Shallow or flat anterior chambers in pseuodophakic eyes are
a serious complication as this may permit the tube or the intra-
ocular lens implant to touch the corneal endothelium leading to
late CEF.
Complications of hypotony do still occur despite tube ligation
of non-valved aqueous shunts, with reports of choroidal effusion
in 16%, shallow or flat anterior chambers in 11% and SCH in
2%.7 9 23 Following AGV implantation, despite the presence of
a valve, a similar rate of these complications still occurs.2 9 14 15
Kee13 described the use of a ligature technique with AGV
reducing postoperative hypotony from 25% to 6%, but we could
not find any reports of the use of C3F8 with the AGV.
The technique of 14%C3F8 gas fill and ligature in our studywas
effective in preventing early hypotony and shallow/flat anterior
chambers in our G&L group. All our serious complications related
to a sudden reduction of IOP postoperatively were seen in the
ahakic/pseudophakic eyeswith standard implantation in groupB.
Although eight eyes developed IOP greater than 30 mm Hgon day
1, this IOPwas on no glaucomamedication. The mean IOP in the
G&Lgroup on the first postoperative daywas 19.4 mm Hg,which
is similar to that reported for non-valved Glaucoma Drainage
Devices (GDD)7 9 23 or following cataract surgery27 or following
cyclodiode laser ablation.28 29
Four cases of aqueousmisdirection occurred in theG&Lgroup in
pseudophakic eyes, three of which had had previous acute angle
closure glaucoma. In the fourth eye the aqueous misdirection
occurred peroperatively before C3F8 injection as it was noted that
there was sudden shallowing of the anterior chamber and the
anterior chamber could not be deepened with a C3F8 gas fill, the
anterior chamber only retaining a very small amount of gas.
Table 1 Patient demographics and characteristics of study population
Gas group
Standard groups
Group A
phakic
Group B
pseudophakic/
aphakic
No of patients 51 21 15
Male 29 13 6
Female 22 15
Race
Caucasian 49 27 15
Black 2 1
Glaucoma type
Primary open angle 18 5 3
Pseudoexfoliation 3 2 1
Uveitic 12 7 5
Post-vitrectomy 7
Aniridia 4
Angle closure 4 2 2
Anterior segment
dysgenesis
2 5 1
Rubeotic 2 1
ICE syndrome 1 1
Post penetrating
keratoplasty
2
Sturge Weber 1
Traumatic 1 2
Previous surgery
Cataract surgery 50 0 15
Vitrectomy 12 1 1
Trabeculectomy 39 21 7
Ahmed valve 6 1
Deep sclerectomy 2
Cyclodiode 1
Lens status
Phakic 1 28
Aphakic 6 4
Pseudophakic 44 11
Ahmed valve model
Model FP-7 7 3 0
Model S-2 44 25 15
Tube cover
No cover 0 2 1
Tutoplast 6 2 e
Tutopatch 6 2 e
Donor sclera 21 15 11
Scleral rotation flap 18 7 3
Mean age, years 66.5617.9
(range 22e90)
50.6617.3
(range 19e78)
65.7614.6
(range 36e80)
Corneal thickness 603.8679.6
(527e1000)
576.6665.0
(515e800)
630.0679.2
(523e745)
No of previous
operations
2.460.9
(range 1e5)
0.960.8 (range
0e2)
2.160.8
(range 1e3)
Presenting IOP (mm Hg) 43.168.2
(range 24e62)
40.1610.7
(range 24e64)
42.567.2
(range 32e60)
ICE, iridocorneal endothelial; IOP, intraocular pressure.
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Table 2 Results
Gas and ligature
group
Standard groups
Group A
phakic
Group B pseudophakic/
aphakic
Mean follow-up, months 23.3613.9 (range 2e48) 28.5622.1 (range 6e84) 49.8622.7 (range 2e72)
Mean IOP
Preoperative 29.867.6 mm Hg
(range 16e50)
31.469.8 mm Hg
(range 16e56)
33.366.5 mm Hg
(range 25e45)
Postoperative
(final visit)
20.067.5 mm Hg
(range 10e50)
18.966.2 mm Hg
(range 7e34)
20.5610.2 mm Hg
(range 12e46)
Percentage change 30.8622.6%
(range 42.9 to 75.5)
34.5624.2%
(range 6.7 to 73.1)
36.2633.6%
(range 43.8 to 69)
Outcome (eyes)
Success 38 (75%) 23 (82.1%) 13 (86.7%)
Complete 16 (30.8%) 11 (39.2%) 2 (13.3%)
Qualified 22 (44.2%) 12 (42.8%) 11 (73.4%)
Failure 12 (25%) 5 (17.9%) 2 (13.3%)
Medication
Preoperative score 3.261.1 (range 1e5) 3.361.6 (range 0e7) 3.560.9 (range 2e5)
Postoperative score (topical) 1.361.2 (range 0e4) 1.060.9 (range 0e3) 1.360.8 (range 0e3)
Complications (eyes)
Early postoperative
IOP >30 mmHg day 1 8 (range 32e45 mm Hg) 0 2
SCH 1
Choroidal detachment 5
Aqueous misdirection 4 1
Iris/vitreous in tube 2
Hyphaema/vitreous haemorrhage 2
Late postoperative
Tube erosion
No cover e 1/2 1/1
Tutoplast 0/6 0/2 e
Tutopatch 1/6 2/2 e
Donor sclera 0/21 0/15 0/11
Scleral rotation flap 3/18 0/7 0/3
Corneal decompensation 1 1 1
Retinal detachment 2
Mild diplopia 4 2 1
Tube repositioning 3
IOP, intraocular pressure; SCH, suprachoroidal haemorrhage.
Figure 2 Change in intraocular
pressure (IOP) with time. Mean
preoperative IOP changed from
29.867.6 to 2067.5 mm Hg (gas
and ligature group), 31.469.8 to
18.966.2 mm Hg (standard phakic
group) and 33.366.5 to
20.5610.2 mm Hg (standard
pseudophakic/aphakic group) at
final visit, a mean change of 30.8,
34.5 and 36.2%. The change in IOP
was statistically significant at all times
postoperatively (p<0.05).
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Therefore, we do not feel gas contributed to the development of
aqueous misdirection, which has been observed in up to 3% of
other studies of tube implants.2 7 11 14 15 All cases responded to
zonulo-hyaloidectomy with anterior vitrectomy through a
peripheral iridectomy as described by Lois et al.24
We had a low incidence of new corneal failure (one eye) devel-
oping postoperatively in our series and we suspect this may be
related to our low incidence of shallow/flat anterior chambers and
hypotony, which reduced the risk of tube/corneal touch. The five
other eyeswithCEFall had significant preoperative corneal disease.
The AGV ‘hypertensive phase’ is an elevation in IOP
occurring within the first 3 months postoperatively, reported to
occur in between 48.5% and 82% of eyes undergoing AGV implan-
tation,2 11 14 15 and to resolve in approximately 30% of cases.14 On
days 1 and 7 themean IOPwas higher in the G&L group than in the
standard groups A and B (figure 2). After day 7 the IOP in the three
groups was very similar during follow-up. In all groups the IOP
peaked at 1 month postoperatively, presumably indicating the peak
of the AGV hypertensive phase. This findingwould seem to indicate
that the only effect on AGV function of gas and ligature was to
elevate the mean IOP temporarily in the first postoperative week.
Therewas no statistically significant difference between the surgical
success rates of AGV implantation between our G&L and standard
groups A and B.
Other studies of AGV implantation report success rates at
12 months of 70.5% to 83%, achieving mean IOP of 16.4 mm Hg
to 18.3 mm Hg on a mean of 1.3 medications, which are similar
to our success rates but with a higher rate of postoperative
hypotony than ours.9 11 13 14
Preventing conjunctival tube erosion
Without a patch graft or scleral flap to cover the tube, there can be
a high rate of tube erosion10 predisposing the eye to the develop-
ment of infectious endophthalmitis.30 31 A rate of tube
exposure of up to 7% following donor scleral patch grafts has been
reported,11 15 32 and although donor sclera for a patch graft was
successful in preventing erosion in our cases, we used the scleral
rotation flap21 method of covering the tube as this avoids the
potential transmission of infection from donor tissue.33 However,
we noted three erosions out of our 28 scleral rotation flap cases and
therefore abandoned this technique latterly and used dried stored
pericardium as a patch cover. Tube erosion has previously been
reported in up to 2.6% of cases in which human pericardium was
used,22 34 35andsowe initiallyusedbovinepericardium(Tutopatch) to
prevent erosion as it is twice as thick. However, with Tutopatch,
a severe inflammationof theconjunctivaoverlying the tubedeveloped
in the first postoperative month in 30% of cases. We therefore aban-
donedTutopatch andhave since used humanpericardium (Tutoplast)
as the tube cover with no inflammation or erosions to date.
CONCLUSIONS
In complex eyes unlikely to respond to conventional filtering
procedures, AGV provides a good long-term rate of success with
a low rate of complications. We had no cases of endophthalmitis
and no cases of persistent hypotony over our 7-year study.
C3F8 gas and temporary Vicryl ligature is a useful technique
for the prevention of postoperative hypotony when implanting
AGV in high-risk eyes, for example, previous vitrectomy, aphakia
or high myopia.
Donor sclera and human pericardium (Tutoplast) appear to be
as effective as patch grafts to prevent conjunctival tube erosion.
CEF was an unusual complication of AGV in our study, and
we feel that the avoidance of hypotony may be an important
factor by preventing shallow or flat anterior chambers and
subsequent tube or lens/corneal endothelial touch.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Coleman AL, Hill R, Wilson MR, et al. Initial clinical experience with the Ahmed
glaucoma valve implant. Am J Ophthalmol 1995;120:23e31.
2. Ishida K, Netland PA, Costa VP, et al. Comparison of polypropylene and silicone
Ahmed glaucoma valves. Ophthalmology 2006;113:1320e6.
Figure 3 KaplaneMeier survival curve
for the groups. KaplaneMeier survival
analysis showed a cumulative
probability of maintaining an intraocular
pressure (IOP) of 6 mm Hg or greater
and 21 mm Hg or less and/or an IOP
drop of 20% or greater for the gas and
ligature group (G&L), standard phakic
group and standard aphakic/
pseudophakic group to be 87.9%, 92.4%
and 86.7% at 1 year and 62.9%, 71.5%
and 86.7% at 4 years, with a mean
survival time of 38.7 months,
66.6 months 62.7 months, respectively.
There was no statistically significant
difference in the survival between
groups (p¼0.19).
1178 Br J Ophthalmol 2010;94:1174e1179. doi:10.1136/bjo.2009.165357
Clinical science
 group.bmj.com on February 9, 2011 - Published by bjo.bmj.comDownloaded from 
3. Ozdal PC, Vianna RN, Deschenes J. Ahmed valve implantation in glaucoma
secondary to chronic uveitis. Eye 2006;20:178e83.
4. Huang MC, Netland PA, Coleman AL, et al. Intermediate-term clinical experience
with the Ahmed glaucoma valve implant. Am J Ophthalmol 1999;127:27e33.
5. Souza C, Tran DH, Loman J, et al. Long-term outcomes of Ahmed glaucoma valve
implantation in refractory glaucomas. Am J Ophthalmol 2007;144:893e900.
6. Minckler DS, Francis BA, Hodapp EA, et al. Aqueous shunts in glaucoma: a report
by the American Academy of Ophthalmology. Ophthalmology 2008;115:1089e98.
7. Gedde SJ, Herndon LW, Brandt JD, et al. Surgical complications in the Tube Versus
Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol 2007;143:23e31.
8. Heuer DK, Lloyd MA, Abrams DA, et al. Which is better? One or two? A randomized
clinical trial of single-plate versus double-plate Molteno implantation for glaucomas in
aphakia and pseudophakia. Ophthalmology 1992;99:1512e19.
9. Tsai JC, Johnson CC, Kammer JA, et al. The Ahmed shunt versus the Baerveldt
shunt for refractory glaucoma II: longer-term outcomes from a single surgeon.
Ophthalmology 2006;113:913e17.
10. Woodcock MG, Richards JC, Murray AD. The last 11 years of Molteno implantation
at the University of Cape Town. Refining our indications and surgical technique. Eye
2008;22:18e25.
11. Ayyala RS, Zurakowski D, Smith JA, et al. A clinical study of the Ahmed glaucoma
valve implant in advanced glaucoma. Ophthalmology 1998;105:1968e76.
12. Coleman AL, Mondino BJ, Wilson MR, et al. Clinical experience with the Ahmed
glaucoma valve implant in eyes with prior or concurrent penetrating keratoplasties.
Am J Ophthalmol 1997;123:54e61.
13. Kee C. Prevention of early postoperative hypotony by partial ligation of silicone tube
in Ahmed glaucoma valve implantation. J Glaucoma 2001;10:466e9.
14. Nouri-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of
the Ahmed glaucoma valve. Am J Ophthalmol 2003;136:1001e8.
15. Susanna R Jr. Partial Tenon’s capsule resection with adjunctive mitomycin C in
Ahmed glaucoma valve implant surgery. Br J Ophthalmol 2003;87:994e8.
16. Canning CR, Lavin M, McCartney AC, et al. Delayed suprachoroidal haemorrhage
after glaucoma operations. Eye 1989;3:327e31.
17. Cantor LB, Katz LJ, Spaeth GL. Complications of surgery in glaucoma.
Suprachoroidal expulsive hemorrhage in glaucoma patients undergoing intraocular
surgery. Ophthalmology 1985;92:1266e70.
18. Ruderman JM, Harbin TS Jr, Campbell DG. Postoperative suprachoroidal
hemorrhage following filtration procedures. Arch Ophthalmol 1986;104:201e5.
19. Franks WA, Hitchings RA. Injection of perfluoropropane gas to prevent hypotony in
eyes undergoing tube implant surgery. Ophthalmology 1990;97:899e903.
20. Freedman J. Scleral patch grafts with Molteno setons. Ophthalmic Surg
1987;18:532e4.
21. Aslanides IM, Spaeth GL, Schmidt CM, et al. Autologous patch graft in tube shunt
surgery. J Glaucoma 1999;8:306e9.
22. Raviv T, Greenfield DS, Liebmann JM, et al. Pericardial patch grafts in glaucoma
implant surgery. J Glaucoma 1998;7:27e32.
23. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the tube
versus trabeculectomy study after one year of follow-up. Am J Ophthalmol
2007;143:9e22.
24. Lois N, Wong D, Groenewald C. New surgical approach in the management of
pseudophakic malignant glaucoma. Ophthalmology 2001;108:780e3.
25. Sathyan P, Singh G, Eong KG, et al. Suprachoroidal hemorrhage following removal of
releasable suture after combined phacoemulsification-trabeculectomy. J Cataract
Refract Surg 2007;33:1104e5.
26. Syam PP, Hussain B, Anand N. Delayed suprachoroidal hemorrhage after needle
revision of trabeculectomy bleb in a patient with hairy cell leukemia. Am J Ophthalmol
2003;136:1155e7.
27. Barak A, Desatnik H, Ma-Naim T, et al. Early postoperative intraocular pressure
pattern in glaucomatous and nonglaucomatous patients. J Cataract Refract Surg
1996;22:607e11.
28. Contreras I, Noval S, Gonzalez Martin-Moro J, et al. [IOP spikes following contact
transscleral diode laser cyclophotocoagulation] (In Spanish). Arch Soc Esp Oftalmol
2004;79:105e9.
29. Walland MJ. Diode laser cyclophotocoagulation: longer term follow up of
a standardized treatment protocol. Clin Experiment Ophthalmol 2000;28:263e7.
30. Al-Torbak AA, Al-Shahwan S, Al-Jadaan I, et al. Endophthalmitis associated with
the Ahmed glaucoma valve implant. Br J Ophthalmol 2005;89:454e8.
31. Krebs DB, Liebmann JM, Ritch R, et al. Late infectious endophthalmitis from
exposed glaucoma setons. Arch Ophthalmol 1992;110:174e5.
32. Melamed S, Cahane M, Gutman I, et al. Postoperative complications after Molteno
implant surgery. Am J Ophthalmol 1991;111:319e22.
33. Centers for Disease Control (CDC). Update: CreutzfeldteJakob disease in
a second patient who received a cadaveric dura mater graft. MMWR Morb Mortal
Wkly Rep 1989;38:37e8, 43.
34. King AJ, Azuara-Blanco A. Pericardial patch melting following glaucoma implant
insertion. Eye 2001;15:236e7.
35. Lama PJ, Fechtner RD. Tube erosion following insertion of a glaucoma
drainage device with a pericardial patch graft. Arch Ophthalmol
1999;117:1243e4.
Br J Ophthalmol 2010;94:1174e1179. doi:10.1136/bjo.2009.165357 1179
Clinical science
 group.bmj.com on February 9, 2011 - Published by bjo.bmj.comDownloaded from 
doi: 10.1136/bjo.2009.165357
December 3, 2009
 2010 94: 1174-1179 originally published onlineBr J Ophthalmol
 
Peter K Wishart, Anshoo Choudhary and David Wong
 
glaucoma: a 7-year audit
Ahmed glaucoma valves in refractory
 http://bjo.bmj.com/content/94/9/1174.full.html
Updated information and services can be found at: 
These include:
References
 http://bjo.bmj.com/content/94/9/1174.full.html#ref-list-1
This article cites 35 articles, 5 of which can be accessed free at:
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on February 9, 2011 - Published by bjo.bmj.comDownloaded from 
